AdAlta’s management team has been responsible for the development of the i-body technology platform, including the identification and pre-clinical development of the lead i-body drug candidate. AdAlta’s management team is focused on progressing the lung fibrosis therapy, AD-214, into the clinic.
Tim Oldham PhD
CEO & MANAGING DIRECTOR
Tim has more than 15 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical product. Tim was appointed CEO and MD in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Co. Industry leadership roles include currently serving as a Director of BioMelbourne Network Inc and terms as chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association. He is a Non-executive Director at Acrux Ltd (ASX:ACR).
Dallas Hartman PhD
Dallas is the Chief Operating Officer of AdAlta and has over 15 years experience in the biotechnology industry. Prior to joining AdAlta, Dallas was Vice President of Product Development at the NASDAQ listed biotechnology company Nexvet where he was responsible for scalable bioprocess development, formulation, stability, analytical characterisation and cell line development. Dallas worked at CSL for 14 years in a number of roles; most notably the Director of Analytical Biochemistry. Before moving to industry, Dallas undertook postdoctoral research at the University of Texas Southwestern Medical Center and the University of Melbourne where his worked was supported by fellowships from the Howard Hughes Medical Institute and the Australian Research Council. Dallas holds an MBA with specialist streams in finance and marketing and was Australasian Bioscience Business Manager for Biolab.
Michael Foley PhD
Founding Chief Scientist and Head of Exploratory Research
Mick is the founding scientist of AdAlta and a key inventor of AdAlta’s lead i-body candidate AD-214. Upon completion of his PhD he was awarded a Wellcome Training Fellowship and worked at the Walter and Elisa Hall Institute. In 1995 Mick was awarded an ARC QEII Fellowship where he established the phage display of antibodies and peptide technology as a means of answering fundamental questions of immunity to infectious diseases. Mick is an internationally recognized leader in phage display, the technology used to screen the i-body library to identify new drug candidates. Having published over 70 scientific publications Mick has received funding from ARC, NHMRC and NIH (US).
Claudia Gregorio-King PhD
Vice President, Clinical Product Development
Claudia has 14 years’ experience as a biotechnology senior manager with highly developed scientific, research and product development skills and a strong track record across small biotechnology and large pharmaceutical companies. Prior to joining AdAlta, she was Vice President of Operations at clinical-stage oncology company, Prescient Therapeutics overseeing the manufacturing, preclinical and clinical programs of Prescient’s two lead drug candidates for the treatment of AML, breast and ovarian cancer. She has held previous regulatory affairs, intellectual property, pre-clinical and clinical management roles within large and small biotechnology & pharmaceutical companies, and contract research organisations both global and Australian. Her experience includes the development of cellular therapies, biologicals, small molecules & gene therapies within Australia and the USA.